Adcetris® (brentuximab vedotin) has been approved by the European Commission for CD30-positive CTCL 

It was announced in a press release on 22nd January 2018, that the European Commission has approved Adcetris® (brentuximab vedotin) for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy. 

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for this indication in November 2017. This followed results from the ALCANZA trial in which brentuximab vedotin demonstrated significantly superior clinical outcomes in patients with CD30-expressing CTCL versus physician's choice

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF